Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Kyn Therapeutics

Kyn Therapeutics is developing a novel approach to target both IDO and TDO mediated immunosuppression through enzymatic degradation of kynurenine systemically and in the tumor microenvironment.  Inhibiting the IDO/TDO pathway is expected to have broad application across many tumor types.

  • Mark Manfredi, PhD Chief Scientific Officer
  • Michelle Zhang, PhD VP, Research and Development
  • Karen McGovern, PhD VP, Translational Research
  • Silvia Coma, PharmD. PhD Principal Scientist